oncology evolved

Learn more

press releases

April 30, 2019

Wugen Adds to Leadership Team as Company Continues to Lay Groundwork for Future Expansion

March 26, 2019

WUGEN Expands Leadership Team with Appointment of a Vice President of Research and Development and a Vice President of Product Development

Feb. 20, 2019

WUGEN Presents New Data for Key CAR-T Platform at the 2019 Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR

abstracts

Modeling Sézary Syndrome for Immunophenotyping and Anti-Tumor Effect of UCART and Long-Acting Interleukin-7 Combination Therapy

A Long-Acting Pharmacological Grade Interleukin-7 Molecule Logarithmically Accelerates UCART Proliferation, Differentiation, and Tumor Killing

View Abstracts

wugen

Careers

Wugen is an Equal Opportunity Employer and does not discriminate against applicants due to race, ethnicity, gender, veteran status, or on the basis of disability or any other federal, state or local protected class.

View Positions

PUBLICATIONS

An “off-the-shelf” fratricide-resistant CAR-T for the Treatment of T-cell hematologic malignancies

T-cell malignancies represent a group of hematologic cancers with high rates of relapse and mortality in patients for whom no effective targeted therapies exist. The shared expression of target antigens between chimeric antigen receptor (CAR) T-cells and malignant T-cells has limited the development.

VIEW PUBLICATION